Aether Biomachines raises $15M in funding. Aether Biomachines, a San Francisco, CA-based company turning AI-designed proteins into real-world solutions, raised $15M in funding. The round was led by Tribe Capital, with participation from new and existing investors including Natural Capital, Henkel Corporation, Resilience Reserve, Shrug Capital, 4DX Ventures, Unless Partners, and Radicle Impact. The company intends to use the funds to expand its Protein Function Model to rapidly design and optimize proteins for industrial and environmental applications, scale its first commercial materials products, and accelerate partnerships with companies looking to apply its AI-powered proteins across manufacturing, sustainability, and national security. Led by CEO and Founder Pavle Jeremić, Aether Biomachines is an American artificial intelligence company that discovers proteins with high-impact, real-world applications. At the core of its work is a Protein Function Model that can generate new proteins for novel functions. Aether's AI is being built on an entirely proprietary dataset developed in-house through advanced high-throughput screening and innovative assay technology. The company says that it is already translating its AI innovations into practice, commercializing high-performance materials that can print faster than current industry benchmarks while offering better strength for the defense and aerospace industries.

Aether Biomachines has raised $15 million in funding led by Tribe Capital, bringing its total funding to $64 million. The company uses AI and high-throughput robotics to design proteins that function as molecular assemblers for industrial applications. Aether's Protein Function Model creates proteins for manufacturing, sustainability and national security purposes. The company has developed seven protein classes with applications including metal refining, breaking down forever chemicals, pharmaceutical manufacturing, plastic recycling and carbon capture. Its AI-designed materials can print ten times faster than current industry standards whilst offering superior strength for defence and aerospace sectors. The funding will expand Aether's protein design capabilities, scale its first commercial materials products and accelerate partnerships across multiple industries. Founded by CEO Pavle Jeremić, the company aims to reduce reliance on global supply chains through domestically produced solutions.

Aether launches RapidPrint 3D printing filament offering at Formnext. A new polymer filament 3D printing offering that promises to 'unlock dramatic acceleration' in the additive manufacturing of high-performance parts has been launched by Aether. Aether describes itself as an American artificial intelligence company that discovers proteins with high-impact, real-world applications. Its RapidPrint technology is said to enable fast print speeds and 'industry-leading mechanical properties', with the company targeting the aerospace, defence and industrial sectors. At Formnext, Aether is demonstrating the capabilities of the technology, as well as its forthcoming 'Ultra Series' of high-strength polymer filaments, on the AON3D Hylo printer. The RapidPrint PA6 CF10 ABX, a modified PA6 with 10% carbon fibre reinforcement, is set to be the first Aether formulation to be released. This material has been engineered for high flow, broad printer compatibility, and excellent surface finish, while 'printing effortlessly between 50-250 mm/s.' With defence and drone manufacturers increasingly relying on additive manufacturing for agile iteration, limited-run production, and field repair, Aether is working to provide material technology that supports high productivity, short development cycles and resilient supply chains. Aether is exhibiting at Formnext from Hall 11.1, Booth E68, with live demos being performed throughout the week.